Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Enterprise Value of -$468.1 million for Q1 2026, down 13.05% on a QoQ basis from -$414.1 million in Q4 2025, and down 23.33% year-over-year from -$610.5 million in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Enterprise Value (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Enterprise Value history runs 10 years deep, the most recent figure standing at -$468.1 million for Q1 2026.
- Quarterly Enterprise Value fell 23.33% year-over-year to -$468.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$468.1 million (down 23.33% YoY) and the FY2025 annual result came in at -$414.1 million, down 69.96% from the prior year.
- Enterprise Value was -$468.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from -$414.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$80.6 million in Q1 2023 and bottomed at -$529.3 million in Q3 2025.
- A 5-year average of -$279.3 million and a median of -$243.6 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 58.25% — and 2024, when it slumped 164.89%.
- Kiniksa Pharmaceuticals International's Enterprise Value stood at -$190.6 million in 2022, then dropped by 8.27% to -$206.4 million in 2023, then declined by 18.05% to -$243.6 million in 2024, then sank by 69.96% to -$414.1 million in 2025, then declined by 13.05% to -$468.1 million in 2026.
- Business Quant data shows KNSA's Enterprise Value at -$468.1 million in Q1 2026, -$414.1 million in Q4 2025, and -$529.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | -468.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -468.09 Mn |
| Dec 31, 2025 | -414.07 Mn |
| Sep 30, 2025 | -529.35 Mn |
| Jun 30, 2025 | -423.53 Mn |
| Mar 31, 2025 | -379.55 Mn |
| Dec 31, 2024 | -243.63 Mn |
| Sep 30, 2024 | -350.18 Mn |
| Jun 30, 2024 | -338.25 Mn |
| Mar 31, 2024 | -213.55 Mn |
| Dec 31, 2023 | -206.37 Mn |
| Sep 30, 2023 | -284.34 Mn |
| Jun 30, 2023 | -184.99 Mn |
| Mar 31, 2023 | -80.62 Mn |
| Dec 31, 2022 | -190.61 Mn |
| Sep 30, 2022 | -200.72 Mn |
| Jun 30, 2022 | -94.31 Mn |
| Mar 31, 2022 | -145.58 Mn |
| Dec 31, 2021 | -182.20 Mn |
| Sep 30, 2021 | -200.18 Mn |
| Jun 30, 2021 | -225.87 Mn |